Drug Type Interferons, Biosimilar |
Synonyms Laferon, Laferonum |
Target |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date UA (01 Jan 2004), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bladder Cancer | UA | 01 Jan 2004 | |
Bone Marrow Neoplasms | UA | 01 Jan 2004 | |
Breast Cancer | UA | 01 Jan 2004 | |
Chlamydia Infections | UA | 01 Jan 2004 | |
Hairy Cell Leukemia | UA | 01 Jan 2004 | |
Hepatitis B | UA | 01 Jan 2004 | |
Herpesviridae Infections | UA | 01 Jan 2004 | |
Human Papillomavirus Infection | UA | 01 Jan 2004 | |
Kaposi Sarcoma | UA | 01 Jan 2004 | |
Melanoma | UA | 01 Jan 2004 | |
Multiple Sclerosis | UA | 01 Jan 2004 | |
Non-Hodgkin Lymphoma | UA | 01 Jan 2004 | |
Ovarian Cancer | UA | 01 Jan 2004 | |
Philadelphia chromosome positive chronic myelogenous leukemia | UA | 01 Jan 2004 | |
Renal Cell Carcinoma | UA | 01 Jan 2004 | |
Sepsis | UA | 01 Jan 2004 |